Wed. 28 Feb 2024, 9:02am ET
Benzinga
Biotech, News, General
- Leading national pharmacy chain to stock GLOPERBA® in majority of their stores throughout the U.S. Scilex is also in the process of negotiating similar potential stocking arrangements with additional pharmacy chains in the U.S.
- For its potential launch expected in the first half of 2024, GLOPERBA® commercial product inventory is available at Scilex's third party logistics service provider, Cardinal Health.
- GLOPERBA® is the first and only liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.
- Gout is a painful arthritic disorder affecting an estimated 9.2 million people in the United States¹. As gout cases increase every year, treatment requirements increase. According to data gathered by Evaluate Pharma, the gout treatment market is projected to reach $2.0 billion in the U.S. by 2028 with a well-defined area of unmet need.²
- Over 70% of gout patients have comorbid conditions that may require precision dose adjustments and such patients could be a potential target population for GLOPERBA®.³
- Scilex increased production of GLOPERBA® and product availability under the brand marketed and distributed by Scilex Pharmaceuticals, Inc. for GLOPERBA®